About NanoCellect Biomedical
NanoCellect Biomedical is a Healthcare company based in San Diego (United States) founded in 2009 by William Alaynick and Jose Morachis. It develops flow cytometry and cell sorting technology. NanoCellect Biomedical has raised $78.15 million across 23 funding rounds from investors including Agilent, NIH and HHS. The company has 84 employees. Its chief executive, as recorded, is Chris Neary. Its website nanocellect.com draws about 13 thousand monthly visits. NanoCellect Biomedical offers products and services including WOLF G2 Cell Sorter, VERLO Image-guided Cell Sorter, N1 Single-Cell Dispenser, and CS1 Chiller-Stirrer. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its legal entity is NanoCellect Biomedical Inc. Its competitors include Singulex, Cell Microsystems and Immunicon; 3 of its 3 listed competitors have raised funding.
Company details
NanoCellect Biomedical is a developer of molecular diagnostics, and improve personalized medicine. The company offers WOLF Cell Sorter, which uses a closed fluid-path microfluidic cartridge that enables cell sorting, and avoids biohazard and shear stress issues associated with traditional cell sorters. It claims that this technology sorts cells at the highest purity with almost no loss of viability. This technology has downstream applications of gene expression and sequencing. It also used in sorting rare cells such as circulating tumor cells (CTCs) from blood samples.
- Headquarters San Diego, United States
- Employees 84
- Founders William Alaynick, Jose Morachis
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nanocellect.com
- Social LinkedIn
- Legal Name Nanocellect Biomedical Inc
- Total Equity Funding$78.15M (USD)
in 23 rounds
- Latest Funding Round$28.93M (USD), Series D
Jun 2023
- InvestorsAgilent
& 12 more
- Employee Count84
Products & Services of NanoCellect Biomedical
NanoCellect Biomedical offers a comprehensive portfolio of products and services, including WOLF G2 Cell Sorter, VERLO Image-guided Cell Sorter, N1 Single-Cell Dispenser, and CS1 Chiller-Stirrer.
Benchtop device for gentle microfluidic cell sorting with high viability.
Image-based tool for precise cell sorting in research applications.
Accessory for single-cell deposition in multi-well plates.
Device for temperature control of samples during sorting.
Funding Insights of NanoCellect Biomedical
NanoCellect Biomedical has successfully raised a total of $78.15M across 23 strategic funding rounds. The most recent funding activity was a Series D round of $28.93 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.15M
- Total Rounds 23
- Last Round Series D — $28.93M
- First Round $166,196
(Aug 2010)
- Investors Count 13
Latest 10 of 23 funding rounds of NanoCellect Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $28.93M | Series D | – | – | – |
| Aug 2022 | $1.8M | Grant | – | – | |
| Aug 2022 | $1.76M | Grant | – | – | |
| Aug 2021 | $20M | Series D | – | Warburg Pincus | |
| Jun 2021 | $15M | Series C | – | Vertical Venture Partners | |
| Oct 2019 | $1.5M | Grant | – | – | |
| Mar 2018 | $1.69M | Grant | – | – | |
| Jan 2018 | Series B | – | – | – | |
| Dec 2017 | $10M | Series B | – | Illumina Ventures | |
| Jul 2017 | $2.47M | Series A | – | – | – |
13 investors in total: 13 institutional.
Investors in NanoCellect Biomedical
NanoCellect Biomedical has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Agilent, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Early-stage venture capital investments are made in specific industry verticals. | vvp.vc | Palo Alto, United States | ||
Investments are made in industrial and life sciences technology companies. | anzupartners.com | Washington, Dc, United States | ||
Early-stage investments are provided by SAGIAN Equity in technology firms. | sagianequity.com | Zionsville, United States | ||
FusionX Ventures is engaged in early-stage startup investments. | fusionxventures.com | San Diego, USA | ||
Venture capital firm backed by Yongjin Group | yjventure.com | Cambridge, United States | ||
Early-stage VC firm focused on life science startups | genoavc.com | San Francisco, United States | ||
Basic research is supported to advance medical sciences. | nigms.nih.gov | Bethesda, United States |
Investor details for NanoCellect Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NanoCellect Biomedical
24 people are tracked at NanoCellect Biomedical (11 in leadership, 7 in board & advisors, 6 in team); the tracked headcount is 84.
| Name | Role | Group |
|---|---|---|
William Alaynick | Co-Founder | Leadership |
Jose Morachis | Co-Founder | Leadership |
Chris Neary | CEO | Leadership |
José Morachis | President & Co-Founder | Leadership |
Aaron Sutherland | VP Of Finance | Leadership |
Olivier Déry | Director of Marketing | Leadership |
Sung Hwan Cho | CTO & Co-Founder | Leadership |
Will Alaynick | Founder & VP, Business Development | Leadership |
Dan Krutkin | R&d Director, Technical Program Management | Leadership |
Olivier Déry PhD. MBA | Director of Marketing | Leadership |
Eric Hansen | Software Engineering Director, Solutions Architect | Leadership |
Yuhwa Lo | Scientific Advisor & Co-Founder | Board & advisors |
Patricia Rogers | Advisor | Board & advisors |
Scott Estes | Advisor | Board & advisors |
Ken Hood | Director | Board & advisors |
Todd Peterson | Director | Board & advisors |
Erica Stone | Advisor | Board & advisors |
Charles Lin | Director | Board & advisors |
Michał Bonar | Distributor Support & Channel Manager - Europe, Middle East And Africa | Team |
Mariah Issa | Marketing Contractor | Team |
4 more people are available in the full profile.
Complete people profiles for NanoCellect Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NanoCellect Biomedical
3 dated milestones of NanoCellect Biomedical across 14 years, from founding to its latest funding, stage changes and deals.
- Founded NanoCellect Biomedical is founded.
- Funding First funding round of $166K.
- Funding Latest funding round, Series D, of $28.9M.
Competitors of NanoCellect Biomedical
NanoCellect Biomedical has 3 listed competitors in our database, 3 of them funded. They include Singulex, Cell Microsystems and Immunicon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| singulex.com | 1997 | Alameda, United States | $140.94M | 236 | Single-molecule counting technology is developed for cardiovascular biomarker detection. | |
| cellmicrosystems.com | 2009 | Durham, United States | $19.1M | Developer of a technology to isolate and recover single cells for molecular analysis | ||
| immunicon.com | 1983 | Bryn Athyn, United States | $75.35M | Cell and molecular-based diagnostics for cancer management are developed. |
Detailed competitors of NanoCellect Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NanoCellect Biomedical
The website of NanoCellect Biomedical (nanocellect.com) receives about 12.8K visits a month.
- Monthly visits12.8K
▼ 29.5% vs previous month
Websites whose visitors overlap most with NanoCellect Biomedical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
invivoscribe.com | invivoscribe.com | 100% | #2,713,213 | – | |
| rosalind.bio | 100% | 9.1K | #2,228,840 | View details | |
| abeomics.com | 81% | #3,028,425 | View details | ||
bio-rad-antibodies.com | bio-rad-antibodies.com | 74% | #287,074 | – | |
| ptglab.com | 74% | #137,673 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for NanoCellect Biomedical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as NanoCellect Biomedical (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nanocellect Biomedical
Complete news archive for NanoCellect Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NanoCellect Biomedical
NanoCellect Biomedical was founded in 2009 and raised its 1st funding round 1 year after it was founded.
NanoCellect Biomedical is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Chris Neary is the CEO of NanoCellect Biomedical, as recorded in our data.
NanoCellect Biomedical is a funded company, having raised a total of $78.15M across 23 funding rounds to date. The company's 1st funding round was a Series A of $2.47M, raised on Aug 2010.
NanoCellect Biomedical has 84 employees.
NanoCellect Biomedical is a developer of molecular diagnostics, and improve personalized medicine. The company offers WOLF Cell Sorter, which uses a closed fluid-path microfluidic cartridge that enables cell sorting, and avoids biohazard and shear stress issues associated with traditional cell sorters. It claims that this technology sorts cells at the highest purity with almost no loss of viability. This technology has downstream applications of gene expression and sequencing. It also used in sorting rare cells such as circulating tumor cells (CTCs) from blood samples.
NanoCellect Biomedical's top competitors include Singulex, Immunicon and Cell Microsystems.
NanoCellect Biomedical offers WOLF G2 Cell Sorter, VERLO Image-guided Cell Sorter, N1 Single-Cell Dispenser, and CS1 Chiller-Stirrer.
NanoCellect Biomedical has 13 investors. Key investors include Agilent, NIH, HHS, Warburg Pincus, and National Institute of General Medical Sciences.
NanoCellect Biomedical operates through Nanocellect Biomedical Inc.